间充质干细胞实现心肌修复:机遇与挑战  

Mesenchymal stem cells for cardiac repair:opportunities and challenges

作　　者：张红强 张冰[1] 李建奇 瞿海龙[1] ZHANG Hongqiang;ZHANG Bing;LI Jianqi;JU Hailong(Emergency Department,Affiliated Hospital of Hebei University,Baoding 071000,China)

机构地区：[1]河北大学附属医院急诊医学科,河北保定071000

出　　处：《医学研究与教育》2022年第5期25-30,共6页Medical Research and Education

摘　　要：间充质干细胞(mesenchymal stem cells,MSCs)是一类存在多种组织内的成体干细胞,主要来源于骨髓、脂肪组织和脐带血。随着对MSCs分离、培养、鉴定的程序化、标准化,使其成为实现心肌修复的理想种子细胞。MSCs植入受损心肌后可分泌多种生物活性物质,抑制心肌重构、促进新生血管形成。然而MSCs体内存活时间短、有形成肿瘤风险,使其尚未大规模应用于临床。为提高MSCs的治疗潜能、保障其治疗安全,基因修饰、药物诱导、生物工程等多种方法从基础走向了临床,使MSCs成为实现心肌修复的优质资源,为心肌梗死、终末阶段心力衰竭带来新的曙光。Mesenchymal stem cells(MSCs)are a kind of adult stem cells residing in a variety of tissues,such as bone marrow,adipose tissue and umbilical cord.With the developments of standard procedures and protocols for isolation,culturing and characterization of these cells,MSCs have emerged as an ideal seed cell for myocardial repair.When transplanted into a injured heart,MSCs have paracrine effects that nurture the injured area,prevent adverse cardiac remodeling,and mediate angiogenesis capabilities.MSCs have short survival time and risk of tumor formation,so they have not been widely used in clinic.In order to improve the therapeutic potential of MSCs and ensure its therapeutic safety,many methods such as gene modification,drug induction and bioengineering have moved from basic research to clinical practices,making MSCs become a high-quality resource cells for myocardial repair,bring new opportunity to myocardial infarction and end-stage heart failure.

关 键 词：心肌梗死 心力衰竭 心肌修复 旁分泌 间充质干细胞 

分 类 号：R54[医药卫生—心血管疾病]